Preferentially Expressed Antigen Of Melanoma Family Member 5 (PRAMEF5)

[Edit]

Preferentially Expressed Antigen Of Melanoma Family Member 5 (PRAMEF5)
PRAMEF5, Belongs to the PRAME family.Contains6 LRR (leucine-rich) repeats. A leucine-rich repeat (LRR) is a protein structural motif that forms an α/β horseshoe fold. It is composed of repeating 20–30 amino acid stretches that are unusually rich in the hydrophobic amino acid leucine. Typically, each repeat unit has beta strand-turn-alpha helix structure, and the assembled domain, composed of many such repeats, has a horseshoe shape with an interior parallel beta sheet and an exterior array of helices. One face of the beta sheet and one side of the helix array are exposed to solvent and are therefore dominated by hydrophilic residues. The region between the helices and sheets is the protein's hydrophobic core and is tightly sterically packed with leucine residues. Leucine-rich repeats are frequently involved in the formation of protein–protein interactions.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Preferentially Expressed Antigen Of Melanoma Family Member 5 (PRAMEF5) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Preferentially Expressed Antigen Of Melanoma Family Member 5 (PRAMEF5) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Preferentially Expressed Antigen Of Melanoma Family Member 5 (PRAMEF5) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Preferentially Expressed Antigen Of Melanoma Family Member 5 (PRAMEF5) CLIA Kit Customized Service Offer
n/a ELISA Kit for Preferentially Expressed Antigen Of Melanoma Family Member 5 (PRAMEF5) ELISA Kit Customized Service Offer
  1. "The DNA sequence and biological annotation of human chromosome 1." Nature 441:315-321(2006) [PubMed] [Europe PMC] [Abstract]
  2. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]